Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David H Fitchett

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
The Canadian Journal of Cardiology|March 8, 2013
Identification and management of patients at elevated cardiometabolic risk in canadian primary care: how well are we doing?Hwee Teoh, Jean-Pierre Després, Robert Dufour, et al.
Circulation|August 23, 2019
Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical TrialSubodh Verma, C David Mazer, Andrew T Yan, et al.
The Canadian Journal of Cardiology|April 5, 2011
Cardiometabolic risk in Canada: a detailed analysis and position paper by the cardiometabolic risk working group, Lawrence A Leiter, David H Fitchett, et al.
The Canadian Journal of Cardiology|April 5, 2011
Identification and management of cardiometabolic risk in Canada: a position paper by the cardiometabolic risk working group (executive summary), Lawrence A Leiter, David H Fitchett, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
The Canadian Journal of Cardiology|March 8, 2013
Identification and management of patients at elevated cardiometabolic risk in canadian primary care: how well are we doing?Hwee Teoh, Jean-Pierre Després, Robert Dufour, et al.
Circulation|August 23, 2019
Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical TrialSubodh Verma, C David Mazer, Andrew T Yan, et al.
The Canadian Journal of Cardiology|April 5, 2011
Cardiometabolic risk in Canada: a detailed analysis and position paper by the cardiometabolic risk working group, Lawrence A Leiter, David H Fitchett, et al.
The Canadian Journal of Cardiology|April 5, 2011
Identification and management of cardiometabolic risk in Canada: a position paper by the cardiometabolic risk working group (executive summary), Lawrence A Leiter, David H Fitchett, et al.
Pageof 6